Vincent Ossipow Net Worth

Vincent Ossipow biography

Dr. Vincent Ossipow Ph.D. serves as Independent Director of the Company. Dr. Ossipow joined Omega Funds, which manages Immunic’s current shareholder, Global Life Bioventure V S.à r.l., in 2014 and subsequently joined NeoMed in 2017. Previously, Dr. Ossipow worked with Sectoral Asset Management, a healthcare institutional investor, as a partner for private investments. From 2000 to 2006 he was a research fellow at the University of Geneva, studying the molecular basis of brain function, and acted as Sectoral Asset Management’s Chief Scientific Officer during this period. Previously, he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund, a biotech-equities listed investment vehicle. Dr. Ossipow trained as a postdoctoral fellow in Geneva (Hoffman-La-Roche and Human Frontier Science Program fellow) and at the National Cancer Institute in Bethesda, MD. He completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business and holds an M.S. in computational sciences, an M.S. in molecular biology, and a Ph.D. in molecular biology, all from the University of Geneva. Dr. Ossipow holds a CFA designation (Chartered Financial Analyst) from the CFA Institute. Ossipow’s extensive experience as a biotechnology investor and analyst, along with his financial and commercial expertise in the biotechnology industry, enable him to contribute important insights to our board on strategic leadership and financial matters and qualify him to serve on our board.

What is the salary of Vincent Ossipow?

As the Independent Director of Immunic, the total compensation of Vincent Ossipow at Immunic is $303,415. There are 9 executives at Immunic getting paid more, with Daniel Vitt having the highest compensation of $2,383,930.

How old is Vincent Ossipow?

Vincent Ossipow is 51, he's been the Independent Director of Immunic since 2019. There are 10 older and 4 younger executives at Immunic. The oldest executive at Immunic, Inc. is Tamar Howson, 72, who is the Independent Director.

What's Vincent Ossipow's mailing address?

Vincent's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.

Insiders trading at Immunic

Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann und Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.

What does Immunic do?

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Immunic executives and stock owners

Immunic executives and other stock owners filed with the SEC include:

• Daniel Vitt,
  President, Chief Executive Officer, Director
• Andreas Muehler,
  Chief Medical Officer
• Manfred Groppel,
  Chief Operating Officer
• Dr. Daniel Vitt,
  CEO, Pres & Director
• Dr. Andreas Muehler Ph.D., M.D.,
  Chief Medical Officer
• Glenn Whaley,
  VP of Fin. and Principal Financial & Accounting Officer
• Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A,
  Exec. Chairman
• Jan Van den Bossche,
  Independent Director
• Jorg Neermann,
  Independent Director
• Vincent Ossipow,
  Independent Director
• Tamar Howson,
  Independent Director
• Barclay Phillips,
  Independent Director
• Jessica Breu,
  IR Contact Officer
• Hella Kohlhof,
  Chief Scientific Officer
• Glenn Whaley,
  Vice President Finance, Principal Financial and Accounting Officer
• Patrick Walsh,
  Chief Bus. Officer
• Inderpal Singh,
  Gen. Counsel
• Dr. Hella Kohlhof,
  Chief Scientific Officer
• Dr. Manfred Gröppel,
  Co-Founder & COO
• Jason Tardio,
  President and COO
• Richard Alan Rudick,
  Director
• Sanjay S Patel,
  Chief Financial Officer
• Joerg Neermann,
  Director
• Manfred Groeppel,
  Chief Operating Officer
• Duane Nash,
  Executive Chairman
• Monika Maria Toernsen,
  Director
• Simona Skerjanec,
  Director